103 related articles for article (PubMed ID: 28476022)
1. ALDH1A3 in CSCs.
Sullivan KE; Cerione RA; Wilson KF
Aging (Albany NY); 2017 May; 9(5):1351-1352. PubMed ID: 28476022
[No Abstract] [Full Text] [Related]
2. The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Sullivan KE; Rojas K; Cerione RA; Nakano I; Wilson KF
Oncotarget; 2017 Apr; 8(14):22325-22343. PubMed ID: 28423611
[TBL] [Abstract][Full Text] [Related]
3. ALDH1A3, a metabolic target for cancer diagnosis and therapy.
Duan JJ; Cai J; Guo YF; Bian XW; Yu SC
Int J Cancer; 2016 Sep; 139(5):965-75. PubMed ID: 26991532
[TBL] [Abstract][Full Text] [Related]
4. ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion.
Zhang W; Liu Y; Hu H; Huang H; Bao Z; Yang P; Wang Y; You G; Yan W; Jiang T; Wang J; Zhang W
PLoS One; 2015; 10(11):e0142856. PubMed ID: 26575197
[TBL] [Abstract][Full Text] [Related]
5. A specific inhibitor of ALDH1A3 regulates retinoic acid biosynthesis in glioma stem cells.
Li J; Garavaglia S; Ye Z; Moretti A; Belyaeva OV; Beiser A; Ibrahim M; Wilk A; McClellan S; Klyuyeva AV; Goggans KR; Kedishvili NY; Salter EA; Wierzbicki A; Migaud ME; Mullett SJ; Yates NA; Camacho CJ; Rizzi M; Sobol RW
Commun Biol; 2021 Dec; 4(1):1420. PubMed ID: 34934174
[TBL] [Abstract][Full Text] [Related]
6. ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells.
Vidovic D; Huynh TT; Konda P; Dean C; Cruickshank BM; Sultan M; Coyle KM; Gujar S; Marcato P
Cell Death Differ; 2020 Jan; 27(1):363-378. PubMed ID: 31197235
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
8. Tissue transglutaminase in the pathogenesis of heart failure.
Shinde AV; Frangogiannis NG
Cell Death Differ; 2018 Mar; 25(3):453-456. PubMed ID: 29238072
[No Abstract] [Full Text] [Related]
9. Transglutaminase is a tumor cell and cancer stem cell survival factor.
Eckert RL; Fisher ML; Grun D; Adhikary G; Xu W; Kerr C
Mol Carcinog; 2015 Oct; 54(10):947-58. PubMed ID: 26258961
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase 2, a double face enzyme.
Beninati S; Piacentini M; Bergamini CM
Amino Acids; 2017 Mar; 49(3):415-423. PubMed ID: 28204961
[No Abstract] [Full Text] [Related]
11. Tissue transglutaminase was up-regulated by EGF-retinoid interplay in epithelial carcinoma cells.
Caccamo D; Currò M; Cannavò G; Ientile R
Life Sci; 2004 Oct; 75(22):2643-52. PubMed ID: 15369700
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem Cells.
Kang S; Oh SC; Min BW; Lee DH
Anticancer Res; 2018 Feb; 38(2):787-794. PubMed ID: 29374703
[TBL] [Abstract][Full Text] [Related]
13. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
Ayinde O; Wang Z; Griffin M
Oncotarget; 2017 Mar; 8(12):20025-20041. PubMed ID: 28223538
[TBL] [Abstract][Full Text] [Related]
14. ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma.
Li G; Li Y; Liu X; Wang Z; Zhang C; Wu F; Jiang H; Zhang W; Bao Z; Wang Y; Cai J; Zhao L; Kahlert UD; Jiang T; Zhang W
Cell Death Dis; 2018 Dec; 9(12):1190. PubMed ID: 30538217
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase and its role in human cancer progression.
Li B; Cerione RA; Antonyak M
Adv Enzymol Relat Areas Mol Biol; 2011; 78():247-93. PubMed ID: 22220476
[No Abstract] [Full Text] [Related]
16. Role of tissue transglutaminase and effect of cantharidinate in human colorectal cancer.
Yang LL; Liang CY; Lu TC; Zhi CY; Liu B; Zhou JH; Liu XM; Gao HC; Huang W
Mol Med Rep; 2013 Dec; 8(6):1812-6. PubMed ID: 24085483
[TBL] [Abstract][Full Text] [Related]
17. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype.
Brown KD
Breast Cancer Res Treat; 2013 Jan; 137(2):329-36. PubMed ID: 23224146
[TBL] [Abstract][Full Text] [Related]
19. Structure and regulation of type 2 transglutaminase in relation to its physiological functions and pathological roles.
Bergamini CM; Collighan RJ; Wang Z; Griffin M
Adv Enzymol Relat Areas Mol Biol; 2011; 78():1-46. PubMed ID: 22220471
[No Abstract] [Full Text] [Related]
20. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
Fisher ML; Adhikary G; Xu W; Kerr C; Keillor JW; Eckert RL
Oncotarget; 2015 Aug; 6(24):20525-39. PubMed ID: 25971211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
